ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months
ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months but have fewer side effects — according to study findings announced at the 2013 ASCO Genitourinary Cancers Symposium in Orlando by Dr Abdenour Nabid from Sherbrooke University in Quebec.